Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up

2016 ◽  
Vol 38 (4) ◽  
pp. 385-393 ◽  
Author(s):  
Giulia Stampacchia ◽  
Adriana Gerini ◽  
Stefano Mazzoleni
Keyword(s):  
Multiple Sclerosis ◽  
Intrathecal Baclofen ◽  
Severe Spasticity ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate

2018 ◽  
Vol 394 ◽  
pp. 127-131 ◽  
Author(s):  
Brian C. Healy ◽  
Bonnie I. Glanz ◽  
Jonathan D. Zurawski ◽  
Maria Mazzola ◽  
Tanuja Chitnis ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

Cognitive Functioning in Multiple Sclerosis

1969 ◽  
Vol 115 (524) ◽  
pp. 765-775 ◽  
Author(s):  
K. L. Jambor
Keyword(s):  
Multiple Sclerosis ◽  
Direct Method ◽  
Cross Sectional Study ◽  
Control Group ◽  
Cross Sectional ◽  
Short Period ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

In previous studies the estimation of the incidence of intellectual changes in multiple sclerosis has varied from as low as 2 per cent. (Cottrell and Wilson, 1926) to as high as 72 per cent. (Ombredane, 1929). In order to establish the incidence accurately, the most satisfactory method would clearly be a long-term follow-up (covering lifetime) of a sample of multiple sclerosis patients. Any cross-sectional study would include patients in varying degrees of advancement of the disease, and patients found to be free of intellectual deficits at the time of investigation would not necessarily remain so. Also, the indirect psychometric assessment of intellectual loss is notoriously difficult, and the direct method of follow-up would give much more accurate results. The only direct study up to date has been that of Canter (1951), who found a highly significant (i.e. 13·48 points) loss on re-testing multiple sclerosis patients on the Army General Classification Test after a four-year period. Even after such a short period as six months he found slight losses on most Wechsler-Bellevue subtests, in contrast to an average gain of six full IQ points of the control group.

scholarly journals Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

2018 ◽  
Vol 9 ◽  
Author(s):  
Maxi Kaufmann ◽  
Rocco Haase ◽  
Undine Proschmann ◽  
Tjalf Ziemssen ◽  
Katja Akgün
Keyword(s):  
Multiple Sclerosis ◽  
Real World ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

393 LONG TERM FOLLOW-UP AFTER CONTINUOUS INTRATHECAL BACLOFEN THERAPY FOR SEVERE SPASTICITY

2010 ◽  
Vol 4 (S1) ◽  
pp. 112-112
Author(s):  
E. Anastasiou ◽  
A. Tzortzopoulou ◽  
A. Alexandropoulou ◽  
K. Rizos ◽  
A. Karakosta ◽  
...  
Keyword(s):  
Intrathecal Baclofen ◽  
Intrathecal Baclofen Therapy ◽  
Severe Spasticity ◽  
Long Term Follow Up

scholarly journals Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab

2014 ◽  
Vol 176 (3) ◽  
pp. 320-326 ◽  
Author(s):  
T. Koudriavtseva ◽  
E. Sbardella ◽  
E. Trento ◽  
V. Bordignon ◽  
G. D'Agosto ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Lymphocyte Subsets ◽  
Peripheral Lymphocyte ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long-term follow-up review of 18 patients

1999 ◽  
Vol 91 (5) ◽  
pp. 733-736 ◽  
Author(s):  
Barry Rawicki
Keyword(s):  
Continuous Infusion ◽  
Nursing Care ◽  
Intrathecal Baclofen ◽  
Content Type ◽  
Implantable Pump ◽  
Severe Spasticity ◽  
Long Term Follow Up ◽  
Fine Print

Object. The goal of this study was to assess the long-term benefits of managing severe spasticity by using continuous infusion of intrathecal baclofen delivered via an implantable pump.Methods. Eighteen patients with severe spasticity of cerebral origin, who failed to respond adequately to more conservative treatments, have been treated with continuous infusion of intrathecal baclofen delivered via an implanted pump. Follow-up review of these patients has lasted between 12 months and 9 years. The patients have been assessed using a variety of tools. Seventeen have had a significant reduction in tone and all have benefited by a reduced need for nursing care or increased function or both.Conclusions. Long-term continuous infusion of intrathecal baclofen delivered via an implantable pump offers an effective method for dealing with otherwise intractable spasticity.

Sign in / Sign up

Export Citation Format

Share Document